HGCO19

The Department of Biotechnology (DBT), Ministry of Science & Technology has has approved additional funding towards clinical studies of India's 'first of its kind' mRNA-based COVID-19 vaccine - HGCO19, developed by Pune-based biotechnology company Gennova Biopharmaceuticals Ltd.

• This funding has been awarded under the 'Mission COVID Suraksha- The Indian COVID-19 Vaccine Development Mission' by DBT's dedicated Mission Implementation Unit at Biotechnology Industry Research Assistance Council (BIRAC).

Advantages of mRNA Vaccines

mRNA vaccines are considered safe as mRNA is non-infectious, non-integrating in nature, and degraded by standard cellular mechanisms.

• They are highly efficacious because of their inherent capability of being translatable into the ....